From November 9, 2023 to December 13, 2023, the company has repurchased 1,314,286 shares, representing 0.93% for KRW 216,584.47 million. With this, the company has completed the repurchase of 1,314,286 shares, representing 0.93% for KRW 216,584.47 million under the buyback announced on November 9, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,79,900 KRW | -1.96% | -6.06% | -10.72% |
24/05 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
10/05 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.72% | 27.12B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.25% | 40.65B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B | |
-8.12% | 11.19B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on November 9, 2023.